Skip to main content

CITADEL ADVISORS LLC

Position in ELVN — Enliven Therapeutics, Inc.

CIK 1423053 MIAMI, FL

Position in ELVN

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$105,001,343
+$36,639,876 QoQ
Shares Held
2,068,992
+18.6% QoQ
Ownership
2.82%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#9
of 210 holders
Holding Since
Mar 2023
14 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ELVN Over Time

Shares Held

Position Value (USD)

Derivatives in ELVN

reported options exposure · as of Jun 30, 2026
CallValue
$0
CallShares
0
PutValue
$3,654,000
PutShares
72,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,088,670,159 across 436 Biotechnology names. ELVN ranks #14 (1.7% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ELVN

Export CSV
30 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $105,001,343 2,068,992
2026-06-30 $3,654,000 72,000
2026-03-31 $68,361,467 1,743,915
2026-03-31 $3,586,800 91,500
2026-03-31 $1,415,120 36,100
2025-12-31 $272,580 17,700
2025-12-31 $21,934,897 1,424,344
2025-09-30 $23,755,496 1,160,503
2025-06-30 $29,496,704 1,470,424
2025-03-31 $3,936 200
2025-03-31 $22,103,355 1,123,138
2025-03-31 $17,712 900
2024-12-31 $39,116,969 1,738,532
2024-12-31 $6,750 300
2024-12-31 $24,750 1,100
2024-09-30 $12,770 500
2024-09-30 $2,554 100
2024-09-30 $44,285,772 1,733,977
2024-06-30 $84,132 3,600
2024-06-30 $14,022 600
2024-06-30 $53,933,613 2,307,814
2024-03-31 $41,413,948 2,354,403
2023-12-31 $33,139,159 2,394,448
2023-09-30 $2,390 175
2023-09-30 $32,121,367 2,351,491
2023-06-30 $46,865,646 2,296,210
2023-06-30 $3,571 175
2023-03-31 $55,297 2,525
2023-03-31 $5,475 250
2023-03-31 $50,286,999 2,296,210